Mon, September 10, 2018
Fri, September 7, 2018
Thu, September 6, 2018
Wed, September 5, 2018
Tue, September 4, 2018

Keay Nakae Maintained (ARWR) at Strong Buy with Increased Target to $25 on, Sep 6th, 2018

Keay Nakae of Chardan Capital, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Increased Target from $18 to $25 on, Sep 6th, 2018.

Keay has made no other calls on ARWR in the last 4 months.



There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Keay's Rating of Hold.



This is the rating of the analyst that currently disagrees with Keay


  • Elemer Piros of "Cantor Fitzgerald" Upgraded from Hold to Buy on, Wednesday, May 9th, 2018